Viewing data from:

PERMETHRIN

ANDA

PERMETHRIN | A074806 | ACTAVIS LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: ELIMITE(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Permethrin (2023)

Total Spending

$10.4M

Total Claims

200,775

Beneficiaries

128,757

Avg Cost/Unit

$0.74

Spending Trend

$15.6M(2019)→$12.4M(2020)→$10.9M(2021)→$10.3M(2022)→$10.4M(2023)

YoY Change:-7.6%

5yr CAGR:-6.4%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain4 active DMFs1 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

DR REDDYS LABORATORIES LTDPERMETHRIN BPC CIS:TRANS/25:75

DMF 117021995

SRIKEM LABORATORIES PVT LTDPERMETHRIN

DMF 280902014

BIOPHORE INDIA PHARMACEUTICALS PVT LTDPERMETHRIN

DMF 302432016

WAVELENGTH ENTERPRISES LTDPERMETHRIN

DMF 311902016

FMC CORPInactivePERMETHRIN

DMF 121451996

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 5%

0 patents0 exclusivities▴

CREAM;TOPICAL | Approved: Jan 23, 1998

No patent or exclusivity listings for this strength.